Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of TQB2868 + anlotinib + chemotherapy versus placebo + chemotherapy as first-line treatment for metastatic pancreatic ductal adenocarcinoma
CTR20253176Phase 3Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Dec 2025
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of TQB2868 in pancreatic adenocarcinoma (PDAC), sponsored by Nanjing Shunxin Pharmaceutical. Started Dec 2025; status: active.
02
Drugs
TQB2868
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20253176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253176.